Bodenheimer H C, Schaffner F, Vernace S, Hirschman S Z, Goldberg J D, Chalmers T
Hepatology. 1983 Nov-Dec;3(6):936-8. doi: 10.1002/hep.1840030609.
Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)-positive chronic hepatitis, may lead to elimination of viral infection, we conducted a controlled trial of the use of the intercalating agent, quinacrine hydrochloride, in treatment of HBsAg-positive chronic hepatitis. No patient converted from HBsAg positive to negative during the trial and no consistent effect on HBV DNA polymerase activity was noted. Following treatment, elevated transaminase values and alterations of HBV markers were observed in several patients. Fluctuations of transaminase values and HBV markers may reflect alterations in host immunity and viral replication. Quinacrine alone is ineffective in therapy of chronic HBV infection. Additional study with intercalating agents, perhaps in conjunction with other drugs, is suggested.
几种能与DNA发生反应的药物在体外可降低乙肝病毒（HBV）DNA聚合酶的活性。鉴于这种病毒复制的改变，若在乙肝表面抗原（HBsAg）阳性的慢性肝炎患者中出现，可能会导致病毒感染的清除，我们进行了一项对照试验，使用嵌入剂盐酸阿的平治疗HBsAg阳性的慢性肝炎。在试验期间，没有患者从HBsAg阳性转为阴性，也未观察到对HBV DNA聚合酶活性有持续的影响。治疗后，在几名患者中观察到转氨酶值升高和HBV标志物的改变。转氨酶值和HBV标志物的波动可能反映了宿主免疫力和病毒复制的变化。单独使用阿的平对慢性HBV感染治疗无效。建议对嵌入剂进行进一步研究，或许可与其他药物联合使用。
